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Objective: To evaluate the effectiveness of metformin therapy in reducing early pregnancy loss in
pregnant women with polycystic ovary syndrome (PCOS).
Materials and methods: This is a prospective cohort study conducted in the Obstetric Department of the
Gulf Medical College Hospital in Ajman, UAE, for a period of 3 years. This study involved 106 nondiabetic
pregnant women with PCOS who became pregnant while using metformin. They were divided into two
groups, namely, the group that received metformin throughout pregnancy (metformin group) and the
group that discontinued using the drug once pregnancy started (control group). A comparison was made
between the two groups of patients with respect to certain basal characteristics (age, body mass index,
previous obstetric outcome, serum glucose with free testosterone). Statistical analysis was performed
using Chi-square test to compare the differences between the two groups.
Results: There were 56 patients who received metformin during pregnancy (metformin group)
compared with 50 patients who did not receive the treatment (control group). The rate of early preg-
nancy loss in the metformin group was 8.9% (5/56) compared with 36% (18/50) in the control group
(p < 0.001). For patients in the metformin group with a history of previous miscarriage, the rate of
pregnancy loss was 45% (35 cases/50 pregnancies).
Conclusion: Metformin therapy in pregnant women with PCOS was associated with a signiﬁcant
reduction in the rate of early pregnancy loss.
Copyright © 2015, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Although the ﬁrst description of polycystic ovary syndrome
(PCOS) is generally credited to Stein and Leventhal (1935), it may
have been observed as early as 1721 when Italian scientist Antonio
Vallinsneri observed larger-than-normal ovaries in young peasant
women, who were moderately obese and infertile [1].
PCOS is the most common cause of anovulatory infertility
worldwide. In addition to poor conception rate, early pregnancy
loss rates are signiﬁcantly higher (30e60%) than in the general
population [2,3]. The etiology of this condition is unknown.
Hyperinsulinemic resistance is implicated as an independent risk
factor for early pregnancy loss due to its adverse effects on endo-
metrial function and implantation environment. Hyperinsulinemiclf Medical College Hospital,
bstetrics & Gynecology. Publishedresistance also plays a key role in the disorder by increasing
androgen concentration and impending ovulation [4,5].
Administration of various insulin-sensitizing drugs such as
metformin has been shown to reduce androgen concentrationwith
restoration of ovarian cycles and reduction of early pregnancy loss
[6].
The beneﬁcial effects of metformin have been reported in pre-
vious studies [7e9] but the question arises whether its use can be
continued throughout pregnancy.Metformin pharmacology
Metformin, a biguanide, is an antihyperglycemic drug, which
improves glucose tolerance. It lowers the basal and postprandial
plasma glucose concentrations. Metformin decreases hepatic
glucose production and intestinal absorption of glucose and im-
proves insulin sensitivity by increasing glucose uptake and utili-
zation [6].by Elsevier Taiwan LLC. All rights reserved.
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stimulating luteinizing hormone (LH), and free testosterone levels
[10]. During pregnancy, the drug passes through the placenta to the
fetus and the fetal serum level becomes comparable to the
maternal level but it is generally considered a safe treatment during
pregnancy [11]. The United States Food and Drug Administration
has classiﬁed the drug as a category Bmedication, suggesting that it
does not appear to cause harm to the fetus in animal studies
[12e14].
It is documented that metformin has beneﬁcial metabolic,
endocrine, vascular, and anti-inﬂammatory effects on the risk fac-
tors contributing to early pregnancy loss [15]. However, its use to
reduce pregnancy complications in women with PCOS is still
controversial [16].
This study was undertaken to evaluate the effect of metformin
therapy on pregnancy outcome by comparing the rate of early
pregnancy loss between two groups of patients who received or did
not receive it throughout the pregnancy period.
Materials and methods
This is a prospective cohort study conducted in the Obstetric
Department of the Gulf Medical Hospital in Ajman between January
2008 and January 2011.
Participants in the studywere 106 nondiabetic pregnant women
who conceived while taking metformin. The patients were divided
into two groups: The ﬁrst group who became pregnant while
receiving metformin and continued the treatment at a dose of
1000 mg/d (metformin group; n ¼ 56) and the second group who
discontinued the use of the drug once pregnancy started because
they were unwilling to continue its use (control group; n ¼ 50).
The study protocol has been revised by the Ethical Committee of
Gulf Medical University, and verbal consent was obtained from the
patients. The complete history of the study patients and their
clinical examination results were completely reviewed to deter-
mine their age, previous history of miscarriage, and body mass
index (BMI).
Speciﬁc investigations of serum analysis were carried out for LH,
thyroid function test, free testosterone level, and oral glucose
tolerance test.
The inclusion criteria of the study were the diagnosis of PCOS
before pregnancy, maternal age of 18e40 years, gestational age
between 5 weeks and 12 weeks, normal serum thyroid-stimulating
hormone and prolactin levels, and pregnancy with singleton fetus.
The exclusion criteria were other risk factors for miscarriage
such as abnormal serum karyotyping for both parents; anti-
phospholipid syndrome, which was excluded by anticoagulant
antibodies test; uterine anomalies as excluded by transvaginal ul-
trasound scanning; and diabetes mellitus by oral glucose tolerance
test.
The diagnosis of PCOS was based on the Rotterdam criteria [17]
implying that at least two of the following three criteria were ful-
ﬁlled: presence of polycystic ovaries ( 9 subcapsular follicles of
10 mm by transvaginal ultrasonography), oligomenorrhea (length
of menstrual cycles > 35 days or < 10 menstrual cycles/y), anov-
ulation, and serum-free testosterone level > 2.5 nmol or clinical
signs of hirsutism.
Pregnancy was detected by serum beta-human chorionic
gonadotropin level > 50 IU/L [18] with conﬁrmation of intrauterine
pregnancy by transvaginal ultrasound scanning. Early pregnancy
loss was deﬁned as spontaneous loss before 12 completed weeks of
pregnancy [19], and was documented as the absence of fetal
viability that was conﬁrmed by the ultrasonography.
For statistical analysis, Chi-square test was used to compare the
differences in the rates of early pregnancy loss between the twogroups and two-tailed test was used for independent samples.
Results were reported as means ± standard deviation and p < 0.05
was considered signiﬁcant.
Results
Table 1 demonstrates the basal clinical and biochemical char-
acteristics of patients in the metformin and control groups. There
were no signiﬁcant differences with respect to maternal age, BMI,
fasting glucose concentration, and serum-free testosterone level
between the metformin and control groups (Table 1).
In the metformin group, nine patients met all the ﬁve criteria of
PCOS described in the Materials and methods section. A total of 15
patients and 20 patients, respectively, met two and three criteria;
12 patients met four of these criteria. In this group, the mean
gestational age was 8.6 ± 0.2 weeks and 50% of the patients (28/56)
became pregnant with the use of clomiphene citrates or human
chorionic gonadotropin for induction of ovulation. Four patients
(7.1%) conceived after in vitro fertilization procedure. None of the
women in the two groups had diabetes mellitus before conception
and all had normal blood glucose level at a range of 5.6 ± 0.6 mmol/
L in themetformin group and 5.2 ± 0.4mmol/L in the control group.
The rate of early pregnancy loss with the results of previous
pregnancy outcome is described in Table 2. Among the 56 women
who received metformin throughout the pregnancy period, there
were ﬁve cases (8.9%) of early pregnancy loss, whereas there were
18 cases (36%) in the control group. The difference was signiﬁcant
(p < 0.001; Table 2).
The results of the previous pregnancy outcome in the patients
studied showed that among the 56women in themetformin group,
there were 25 cases with a positive history of early pregnancy loss
in previous pregnancies and 31 had a negative history. Patients
with a negative history of early pregnancy loss were either primi-
gravidas or cases with previous successful pregnancies. None of the
patients had received metformin in the previous pregnancies.
Among the 25 women in the metformin group with a history of
previous pregnancies, therewere 50 pregnancies (15 live births and
35 miscarriages), with a miscarriage rate of 45%.
In the control group, 20 (40%) of the 50 women had a history of
previous pregnancy loss, whereas 30 cases were primigravidas.
Among the 20 womenwith previous pregnancy loss, there were 25
pregnancies, which resulted in 16 live births and nine miscarriages,
yielding amiscarriage rate of 36%. For the patients in themetformin
group with a previous history of early pregnancy loss, there was a
reduction in the rate of pregnancy loss from 45% in the previous
pregnancies to 8.9% in the present pregnancies. In the control group,
however, there were no signiﬁcant differences between the rates in
the previous and present pregnancies (40% vs. 35%), respectively.
The analysis of the effect of metformin on the maternal
androgen and BMI shows that there was a signiﬁcant reduction in
the level of free testosterone in the serum of patients in the met-
formin group compared with those in the control group
(1.6 ± 0.5 nmol/L vs. 4.2 ± 0.7 nmol/L). However there were no
signiﬁcant differences of BMI in the two groups. In addition, it was
observed that most cases of pregnancy loss in the metformin and
control groups were associated with elevated serum-free testos-
terone level (> 4 nmol/L) and higher BMI (> 29 kg/m2; Table 3).
Metformin was well tolerated in all patients. None of the pa-
tients required cessation or reduction in the treatment dose. No
side effects or serious complications were observed.
Discussion
Women with insulin resistance are at increased risk of hyper-
insulinemia, PCOS, and hyperandrogenism [4,5]. They are also at
Table 1
Basal clinical characteristics of patients with polycystic ovary syndrome before pregnancy who either receivedmetformin (metformin group) or did not receive (control group)
metformin throughout pregnancy.
Basal characteristics Metformin group N ¼ 56 Control group N ¼ 50 p
Maternal age (y) 28.1 ± 1.6 28.6 ± 1.5 0.1
Body mass index (kg/m2) 28.4 ± 1.8 27.8 ± 1.3 0.4
Gestational age (wk) 8.6 ± 0.7 8.7 ± 0.5 0.2
Fasting serum glucose (mmol/L) 5.6 ± 0.6 5.2 ± 0.4 0.1
Number of criteria met (mean-þ) 3.5 ± 1.6 3.6 ± 1.3 0.2
Serum-free testosterone (mmol/L) 4.8 ± 0.5 4.6 ± 1.4 0.2
Proportion of patients who received drugs for induction of ovulation (Clomid or gonadotropin) 28 (50)a 30 (60)b 0.4
Proportion of patients conceived after in vitro fertilization 4 (7.1) 3 (6) 0.2
a Continuous variables are presented as mean ± standard deviation.
b Categorical variables presented as n (%).
Table 2
Rate of early pregnancy loss in the metformin and control groups with previous pregnancy outcome.
Cohort Metformin group N ¼ 56 (%) Control group N ¼ 50 (%) p
Rate of pregnancy loss in the present pregnancy 5 (8.95) 18 (36) <0.01
Positive history of early pregnancy loss in previous pregnancy 25 (44.6) 20 (40) 0.4
Negative history of early pregnancy loss in previous pregnancy 31 (55.3) 30 (60) 0.2
Rate of early pregnancy loss in previous pregnancy 35 (45)a 9 (36)b <0.01
Data are presented as n (%).
a Among the 25 women in the metformin group, there were 50 pregnancies with pregnancy loss in 35 cases (45%).
b Among the 20 women in the control group, there were 25 pregnancies with a pregnancy loss in nine cases (36%).
Table 3
Maternal serum androgen level and body mass index in pregnant women with polycystic ovary syndrome in the two study groups.
Maternal serum androgen (free testosterone) level and BMI Metformin group (n ¼ 56) Control group (n ¼ 50) p
Serum-free testosterone (nmol/L) 1.56 ± 0.6 4.2 ± 0.7 <0.001
BMI (kg/m2) 29.4 ± 2.3 29.6 ± 1.2 0.3
BMI ¼ body mass index.
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mal hormonal milieu that may impair conception and implantation
[20]. This emphasizes the need for a treatment using drugs such as
metformin, which will actively reduce insulin resistance, and will
restore ovulatory cycles and reduce early pregnancy loss [6]. In
addition to this there is accumulating evidence suggesting that this
drug is probably safe in the ﬁrst trimester of pregnancy despite the
traditional response that all oral hypoglycemic agents are contra-
indicated in pregnancy [14].
The ﬁndings of this study support the previous reports that
stated that decreasing insulin resistance with metformin inwomen
with PCOS decreases the rate of early pregnancy loss [20e23]. In
our analysis, it is observed that there was a dramatic reduction in
the rates of early pregnancy loss in the metformin group compared
with the control group. The early pregnancy loss rate of 8.9% is
comparable to the rate of 8.8 reported by Jakubowicz et al [9] and to
the rate of 11% reported by Glueck et al [23] in another pilot study. It
is observed in this analysis that the rate of cumulative early preg-
nancy loss in all previous pregnancies was high in the metformin
group; however, the heterogeneity of individuals should also be
considered in this condition.
It is reported that the beneﬁcial role of metformin is indepen-
dent of its hypoglycemic activity but occurs through the effect on
lipid, inﬂammation, hemostasis, endothelial cells, and platelet
function [15,24e27]. In addition to these, there are several mech-
anisms for the action of this drug in patients with PCOS. One major
effect is brought about by the reduction of the hyper-
androgenization of the embryo [28,29]. In addition to the effect of
immunoglobulin G-binding protein, which seems to facilitate the
adhesion process at the endometrial interface [30].This study showed that maternal serum androgen level was
reduced signiﬁcantly after metformin treatment. This is in agree-
ment with the studies of Sarlis et al [31] and Glueck et al [21];
however, our results are in contrast to those of Vanky et al [32], who
reported that the maternal androgen level was more or less unal-
tered during pregnancy or it had no major effect on pregnancy.
An analysis of the effects of BMI in both groups of patients shows
that although the mean BMI was not signiﬁcantly different, high
BMI was associated with a higher rate of early pregnancy loss.
These observations may be explained by the adverse effect of high
insulin resistance, which is more prominent with high BMI [33].
Nausea and mild gastrointestinal symptoms are the most
frequent side effects of metformin treatment [34]. It is anticipated
that this treatment might exaggerate the morning sickness of
pregnancy. However, it was well tolerated in all patients, with no
serious complications.
In conclusion, the use of metformin in pregnant women with
PCOS during pregnancy was associated with a signiﬁcant reduction
in the rates of early pregnancy loss. It was well tolerated by patients
with a minimum of side effects. However, extended studies are
required to evaluate its effect on further pregnancy complications.
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